## **GABRA1** Antibody


PACO19687



Product Information	
Size:	Protein Background:
50ul	Signal transducer and transcription activator that mediates cellular responses to
Reactivity:	interferons (IFNs), cytokine KITLG/SCF and other cytokines and other growth factors. Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors,
Human, Mouse, Rat	signaling via protein kinases leads to activation of Jak kinases (TYK2 and JAK1) and to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize and associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of IFN-stimulated genes (ISG), which drive the cell in an antiviral state. In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine- phosphorylated. It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to
Source:	
Rabbit	
lsotype:	
lgG	
Applications:	drive the expression of the target genes, inducing a cellular antiviral state.
ELISA, WB, IHC	Gene ID:
Recommended dilutions:	GABRA1
ELISA:1:2000-1:5000, WB:1:500-1:2000,	Uniprot
IHC:1:25-1:100	P14867
	Synonyms:
	gamma-aminobutyric acid, (GABA) A receptor, alpha 1
	Immunogen:
	Synthetic peptide of human GABRA1.

## Storage:

-20° C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol



72-

55-

36-

28-

The image on the left is immunohistochemistry of paraffin-embedded Human gastric cancer tissue using PACO19687(GABRA1 Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: x—200).

Gel: 8%SDS-PAGE, Lysate: 40 μ g, Lane: LoVo cells, Primary antibody: PACO19687(GABRA1 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute.

The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using PACO19687(GABRA1 Antibody) at dilution 1/30, on the right is treated with synthetic peptide. (Original magnification: x—200).

